Comirnaty developers Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) continue to broaden the impact of the vaccine, with a new regulatory submission in the USA.
The firms have submitted an application to the US Food and Drug Administration for Emergency Use Authorization (EUA) for an additional booster dose for the coronavirus vaccine.
This would cover adults 65 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze